휴비츠
Financials
Valuation Metrics
휴비츠's Market Cap is ₩686B. At end of 2025 it was ₩996B. Ranked #1497 of 2,410 in KR market (top 62%), #864 of 1,631 on KOSDAQ (top 53%), #57 of 94 in Health Care Equipment & Services (top 61%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 68.64B KRW | KR#1,497/2,410 Sec#57/94 |
| Revenue | 121.23B KRW | KR#1,308/2,410 Sec#25/94 |
| Net Income | -1.40B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 230.69B KRW | KR#1,212/2,410 Sec#31/94 |
| Net Assets | 114.86B KRW | KR#1,315/2,410 Sec#40/94 |
| Employees | 271 | KR#869/2,410 Sec#26/94 |
| Value | ||
| P/B | 0.60x | KR#1,047/2,410 Sec#16/94 |
| P/S | 0.57x | KR#1,048/2,410 Sec#12/94 |
| EV/EBITDA | 27.49x | KR#1,179/2,410 Sec#38/94 |
| FCF Yield | 8.03% | KR#715/2,410 Sec#18/94 |
| Profitability | ||
| ROE | -1.22% | KR#1,641/2,410 Sec#54/94 |
| ROA | -0.61% | KR#1,629/2,410 Sec#54/94 |
| Op. Margin | 4.27% | KR#1,059/2,410 Sec#41/94 |
| Revenue Growth | 1.88% | KR#1,391/2,410 Sec#69/94 |
| Earnings Growth | -227.57% | KR#1,245/2,410 Sec#45/94 |
| Financial Health | ||
| Debt Ratio | 100.84% | KR#1,558/2,410 Sec#78/94 |
| Total Debt | 77.86B KRW | KR#816/2,410 Sec#16/94 |
| FCF | 5.51B KRW | KR#876/2,410 Sec#24/94 |
| Cash | 4.26B KRW | KR#2,061/2,410 Sec#77/94 |
| Current Ratio | 1.10x | KR#1,600/2,410 Sec#76/94 |
| Net Debt/EBITDA | 14.22x | KR#1,315/2,410 Sec#43/94 |
| Dividend | ||
| Div. Yield | 3.96% | KR#498/2,410 Sec#4/94 |
| Div. Growth | 25.00% | KR#391/2,410 Sec#16/94 |
| Performance | ||
| 1Y Return | -23.52% | KR#1,282/2,410 Sec#40/94 |
| 1M Return | -11.00% | KR#883/2,410 Sec#34/94 |
| From 52W High | -37.46% | KR#685/2,410 Sec#24/94 |
| 1Y MDD | -36.73% | KR#447/2,410 Sec#10/94 |
| Trading | ||
| Volume | 5,776 shares | KR#1,347/2,410 Sec#55/94 |
| Trading Value | 36.3M KRW | KR#1,245/2,410 Sec#51/94 |
| Foreign Own. | 3.07% | KR#1,266/2,410 Sec#43/94 |
| Per Share | ||
| EPS | -129 KRW | KR—/2,410 Sec—/94 |
| BPS | 10,559 KRW | KR#956/2,410 Sec#19/94 |
Company Info
Huvitz, established in 1999 and listed on the KOSDAQ market in 2003, plans to expand its implant business by acquiring shares in Osview in 2025. As a specialized ophthalmic medical device company, Huvitz produces South Korea's first optical coherence tomography diagnostic devices and auto refractometers, expanding its business across all optometric fields. The company invests over 10% of its annual revenue in research and development, with R&D personnel comprising 33% of its workforce, growing into a top-tier company in the ophthalmic diagnostic field. Huvitz is headquartered in Anyang-si, Gyeonggi-do.